Rapporterte hendelser med Sutent ved metastatisk nyrekreft

Selekterte rapporterte hendelser fra registreringsstudien ved behandling av metastatisk nyrekreft

* Listed are all treatment-related adverse events of interest and those occurring in at least 10% of patients in the sunitinib group. All severity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.
† The comparison between the sunitinib group and the interferon alfa group was significant (P<0.05) with the use ofFisher’s exact test applied to the sum of grade 3 and 4 adverse events. The significance of the comparison between treatment groups for “all grades” of adverse events is not shown.


Referanse:

  • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib vs Interferon Alfa in Metastatic Renal-Cell Carcinoma. N Engl Med 2007.356:115-124.


For bivirkninger sett ved behandling av GIST og pNET se Sutent SPC